Nerviano, 03.04.2019

At AACR meeting Nerviano Medical Sciences presents new evidences on its own FLT3/KIT/CSF1R inhibitor and its activities on the identification and characterization of ATP-mimetic choline kinase inhibitors.

These new activities and evidences come from the Kinase platform in Nerviano Medical Sciences, an integrated system of know-how, technologies and intellectual property developed over the years that allows the research Campus a conspicuous synergy in the efficient development of innovative anticancer drugs.
Read more +
Nerviano, 08.03.2019

NMS Group is the sponsor of the Eighth Edition of China Career Day

Agazzi, Chairman of NMS Group: “In the research field challenges know no boundaries by definition and they must be faced through a wide and global approach. With this perspective, for all Group' companies it is essential to become an attractive organization for young talents from all over the world. This initiative of the Italy-China Foundation certainly goes in the right direction and it represents a concrete action to support employers."
Read more +
South San Francisco, CA, 18.02.2019

FDA Grants Priority Review to Entrectinib

Nerviano Medical Sciences is the Originator of Entrectinib, now licesed to Ignyta (Roche Group). Read more on the development of this investigational, oral medicine.
Read more +